Trial Profile

A Safety Study of ARRY-502 in Healthy Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 07 Oct 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ARRY 502 (Primary)
Indications Allergic asthma; Seasonal allergic rhinitis
Focus Adverse reactions; Pharmacokinetics
Sponsors Array BioPharma; Pfizer

Most Recent Events

30 Jan 2012 Results were published in a Array BioPharma media release.
19 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
10 Aug 2011 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com